“…While p62 accumulation in hepatocytes, due to partial autophagy inhibition, inflammation, and oxidative stress, leads to non-mutational activation of mTORC1 that can initiate hepatocellular carcinoma (HCC) development [28]••, hepatic stellate cell (HSC)-specific KO of p62 potentiates liver fibrosis, inflammation, and HCC progression [29]••. Importantly, full-body KO of p62, in the context of a commonly used HCC inducer cocktail, diethylnitrosamine (DEN), and high-fat diet administration, enhanced HCC development [29]••, which suggests that the tumor-suppressor role of p62 in the stromal fibroblast compartment [20,23,29] outweighs its tumor-promoting effects in the tumor epithelium [27–31]. Mechanistic studies revealed that p62 loss in the HSC compartment reduced the anti-fibrotic and anti-inflammatory effects of vitamin D receptor (VDR) agonists, thus promoting HSC activation [29]•• (Figure 3B).…”